Indeed, treatment with TGF-β signaling inhibitor SB525334 reverts the FASN (fatty acid synthase)-mediated resistance to NK cell cytotoxicity in cisplatin resistant lung cancer, probably through the modulation of PD-L1 levels on tumor cells. This evidence concerns the gene TGFB1 and lung carcinoma.